Table 3.
Adverse events suspected to be related to sunitinib
| Adverse event | N = % | |
|---|---|---|
| All grade | Grade 3 or grade 4 | |
| Fatigue | 17 (68) | 4 (16) |
| Nausea/Vomiting | 16 (64) | 2 (8) |
| PPES | 16 (64) | 2 (8) |
| Diarrhoea | 11 (44) | 1 (4) |
| Hypertension | 11 (44) | 2 (8) |
| Mucositis | 10 (40) | 1 (4) |
| Dysguesia | 7 (28) | 0 (0) |
| Anorexia | 5 (20) | 0 (0) |
| Thrombocytopenia | 6 (24) | 4 (16) |
| AST/ALT increased | 3 (12) | 1 (4) |
| Anaemia | 3 (12) | 2 (8) |
| Hypothyroidism | 3 (12) | 0 (0) |
| Neutropenia | 3 (12) | 1 (4) |
| Elevated creatinine | 3 (12) | 0 (0) |
| Hyponatraemia | 2 (8) | 2 (8) |
| Cardiac ischaemiaa | 1 (4) | 1 (4) |
| Cardiomyopathy | 1 (4) | 1 (4) |
All patients were counted once at the highest grade for each preferred term Adverse events were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version X)
PPES palmar-plantar erythrodysesthesia syndrome
aThe cardiac ischaemic event occurred following episodic hypertensive episodes
All grade 3/4 events are reported, only grade 1/2 occurring in more than 2 patients are documented